← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA98.1x16.2x24.1x
EV / LTM revenue180.8x1.1x2.2x
Premium to unaffected price2424%35%60%
Premium to 30-day VWAP0Too thin to quote. Widen the cut.

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
0352010: 1 deals, 0 clean on every measure201012011: 2 deals, 1 clean on every measure201122012: 5 deals, 5 clean on every measure201252013: 2 deals, 0 clean on every measure201322014: 3 deals, 1 clean on every measure201432015: 2 deals, 1 clean on every measure201522016: 3 deals, 1 clean on every measure201632018: 4 deals, 3 clean on every measure201842019: 3 deals, 0 clean on every measure201932021: 4 deals, 3 clean on every measure202142022: 4 deals, 4 clean on every measure202242023: 2 deals, 2 clean on every measure202322025: 2 deals, 0 clean on every measure202522026: 1 deals, 0 clean on every measure20261
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 16.2x median across 9 dealsHealthcare16.2xn=9
Deals by sector
Healthcare: 38 dealsHealthcare38
Deals by buyer type
Financial sponsor: 3 dealsFinancial sponsor3Strategic: 38 dealsStrategic38Management / founder: 0 dealsManagement / founder0Controlling holder: 0 dealsControlling holder0Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 23 dealsUnclassified23
Deals by enterprise value
Under $250m: 10 dealsUnder $250m10$250m to $1bn: 8 deals$250m to $1bn8$1bn to $5bn: 10 deals$1bn to $5bn10$5bn to $20bn: 9 deals$5bn to $20bn9Over $20bn: 1 dealsOver $20bn1Not computed: 0 dealsNot computed0
Deals by industry code
Depository Institutions: 206 dealsDepository Institutions206Business Services & Software: 186 dealsBusiness Services & Sof…186Chemicals, Pharmaceuticals & Allied Products: 148 dealsChemicals, Pharmaceutic…148Electronics & Electrical Equipment: 118 dealsElectronics & Electrica…118Instruments, Medical Devices & Optical Goods: 91 dealsInstruments, Medical De…91Holding & Other Investment Offices: 76 dealsHolding & Other Investm…76Oil & Gas Extraction: 71 dealsOil & Gas Extraction71Industrial Machinery & Computers: 61 dealsIndustrial Machinery & …61Electric, Gas & Sanitary Services: 58 dealsElectric, Gas & Sanitar…58Communications: 53 dealsCommunications53
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Talkspace, Inc.
2026-03-09 · Public merger · $5.25 a share
Held out of the multiples: EV / LTM EBITDA 138.7x outside 1x to 75x
Universal Health Services, Inc.
Strategic
Healthcare$832m138.7x3.6x
10%
DEFM14A
All cash
Exact Sciences Corp
2025-11-19 · Public merger · $105.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Abbott Laboratories
Strategic
Healthcare$19bnn.a.6.1x
51%
DEFM14A
Includes stock
Sunlink Health Systems Inc
2025-01-03 · Public merger · $5.00 a share
Held out of every statistic: consideration includes stock: the cash figure is not the price; premium of 204%: distressed or misread
Restated Agreement
Strategic
Healthcare$27mn.a.0.9x
204%
DEFM14A
Includes stock
Amedisys Inc
2023-06-26 · Public merger · $101.00 a share
UnitedHealth Group Incorporated
Strategic
Healthcare$3.6bn18.4x1.6x
29%
DEFM14A
All cash
Oak Street Health, Inc.
2023-02-07 · Public merger · $39.00 a share
CVS Pharmacy, Inc.
Strategic
Healthcare$10bnn.a.4.6x
n.a.
DEFM14A
All cash
Signify Health, Inc.
2022-09-02 · Public merger · $30.50 a share
CVS Pharmacy, Inc.
Strategic
Healthcare$5.3bnn.a.6.3x
n.a.
DEFM14A
All cash
1Life Healthcare Inc
2022-07-20 · Public merger · $18.00 a share
Amazon.com, Inc.
Strategic
Healthcare$3.1bnn.a.3.5x
83%
DEFM14A
All cash
LHC Group, Inc
2022-03-28 · Public merger · $170.00 a share
UnitedHealth Group Incorporated
Strategic
Healthcare$5.4bn26.0x2.4x
11%
DEFM14A
All cash
Apria, Inc.
2022-01-07 · Public merger · $37.50 a share
Owens & Minor, Inc.
Strategic
Healthcare$1.5bn7.1x1.3x
26%
DEFM14A
All cash
Diversicare Healthcare Services, Inc.
2021-08-26 · Public merger · $10.10 a share
Held out of the premiums: premium of 256%: distressed or misread
Support Agreement
Strategic
Healthcare$104m4.3x0.2x
256%
DEFM14A
All cash
GeneDx Holdings Corp.
2021-02-09 · Public merger · $10.00 a share
Inc.
Strategic
Healthcare$130mn.a.0.7x
n.a.
DEFM14A
All cash
Talkspace, Inc.
2021-01-12 · Public merger · $10.00 a share
Groop Internet Platform, Inc.
Strategic
Healthcare$133mn.a.1.7x
n.a.
DEFM14A
All cash
Magellan Health Inc
2021-01-04 · Public merger · $95.00 a share
Centene Corporation
Strategic
Healthcare$1.8bnn.a.0.4x
32%
DEFM14A
All cash
Genomic Health Inc
2019-07-28 · Public merger · $27.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Exact Sciences Corporation
Strategic
Healthcare$776m12.7x1.8x
n.a.
DEFM14A
Includes stock
AdaptHealth Corp.
2019-07-08 · Public merger · $10.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
DFB Healthcare Acquisitions Corp.
Strategic
Healthcare$312mn.a.0.9x
n.a.
DEFM14A
Includes stock
Option Care Health, Inc.
2019-03-14 · Public merger · $2.20 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
HC Group Holdings II, Inc.
Strategic
Healthcare$807m23.4x1.1x
n.a.
DEFM14A
Includes stock
Civitas Solutions, Inc.
2018-12-18 · Public merger · $17.75 a share
Celtic Intermediate Corp.
Strategic
Healthcare$1.3bn8.9x0.8x
n.a.
28% to VWAP
DEFM14A
All cash
Birner Dental Management Services Inc
2018-10-03 · Public merger · $10.62 a share
Mid-Atlantic Dental Services Holdings, LLC
Strategic
Healthcare$26mn.a.n.a.
105%
DEFM14A
All cash
Legacy Lifepoint Health, Inc.
2018-07-22 · Public merger · $65.00 a share
LifePoint Health, Inc.
Strategic
Healthcare$5.3bnn.a.n.a.
36%
DEFM14A
All cash
Envision Healthcare Corp
2018-06-10 · Public merger · $46.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
AmSurg Corp.
Strategic
Healthcare$9.4bnn.a.1.2x
n.a.
DEFM14A
Includes stock
USMD Holdings, Inc.
2016-08-29 · Public merger · $22.34 a share
WellMed Medical Management, Inc.
Strategic
Healthcare$269mn.a.0.8x
89%
DEFM14C
All cash
Envision Healthcare Holdings, Inc.
2016-06-15 · Public merger · $66.26 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
AmSurg Corp.
Strategic
Healthcare$15bn26.2xn.a.
n.a.
DEFM14A
Includes stock
Amsurg Corp
2016-06-15 · Public merger · $66.26 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Envision Healthcare Holdings, Inc.
Strategic
Healthcare$5.9bn7.9x2.2x
n.a.
DEFM14A
Includes stock
IPC Healthcare, Inc.
2015-08-04 · Public merger · $80.25 a share
Team Health Holdings, Inc.
Strategic
Healthcare$1.5bn24.1x2.3x
45%
DEFM14A
All cash
Bio Reference Laboratories Inc
2015-06-03 · Public merger · $50.35 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Bamboo Acquisition, Inc.
Strategic
Healthcare$1.4bn11.9xn.a.
60%
DEFM14A
Includes stock

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More